Literature DB >> 6709646

Cleavage of the Arg1-Pro2 bond of bradykinin by a human lung peptidase: isolation, characterization, and inhibition by several beta-lactam antibiotics.

W Sidorowicz, J Szechiński, P C Canizaro, F J Bĕhal.   

Abstract

An aminopeptidase P (EC 3.4.11.9) that cleaves the Arg1-Pro2 bond of bradykinin has been isolated for the first time from human lung and purified 473-fold. The enzyme also catalyzes the cleavage of arginine from des-[Arg9]-bradykinin and the hydrolysis of several X-proline dipeptides including L-arginyl-L-proline, L-leucyl-L-proline, and L-alanyl-L-proline. Purified enzyme was routinely assayed (after initial identification with des-[Arg9]-bradykinin) with L-leucyl-L-proline. The molecular weight, in nondenaturing buffers, is 188,000 +/- 8500 Da. The pH optimum was 8.0 with arginyl-proline, and was 6.8 with leucyl-proline. Chelating agents do not inactivate the enzyme, but rather only remove loosely bound cations that stimulate the enzyme. Manganese is the principal cation that stimulates the enzyme. The enzyme is inhibited by several beta-lactam antibiotics, cephalexin and oxacillin being the most effective of those tested. The antibiotic inhibition is time and temperature dependent, and it is not fully reversible by exhaustive dialysis of the antibiotic-treated enzyme.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6709646     DOI: 10.3181/00379727-175-41828

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  4 in total

1.  Aminopeptidase P from bovine lung: solubilization, properties, and potential role in bradykinin degradation.

Authors:  A T Orawski; J P Susz; W H Simmons
Journal:  Mol Cell Biochem       Date:  1987-06       Impact factor: 3.396

2.  A high-molecular-mass neutral endopeptidase-24.5 from human lung.

Authors:  R Zolfaghari; C R Baker; P C Canizaro; A Amirgholami; F J Bĕhal
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

Review 3.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

Review 4.  Targeting inhaled therapy beyond the lungs.

Authors:  Ninell P Mortensen; Anthony J Hickey
Journal:  Respiration       Date:  2014       Impact factor: 3.966

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.